Genetics, In-Vivo and Life Science - Clinical Research Informer

Life Science Trends to Look Out for in 2024

XTalks

DECEMBER 20, 2023

As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables.

Life Science

Life Science Gene Editing Development Clinical Trials

Intellia Gets FDA Clearance to Start First Ever Phase III Trial for an In Vivo CRISPR Drug

XTalks

OCTOBER 20, 2023

Intellia said NTLA-2001 is the first investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development. As an in vivo therapy, it can edit genes inside the body rather than in cells extracted from patients. ATTR amyloidosis is a rare, progressive and fatal disease.

In-Vivo

In-Vivo Gene Editing Trials Gene

Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective

Pharmaceutical Technology

MAY 24, 2023

The ability to modify or introduce genetic material in human cells in such a precise and patient-centered manner clearly constitutes a breakthrough in personalized medicine. CGT drugs fall into two major categories: autologous and allogeneic. What are the general differences in the supply chain of CGT vs. traditional clinical trials?

Clinical Trials

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Gulf War Illness: How can disease modelling aid the search for a cure?

pharmaphorum

OCTOBER 6, 2022

By reducing the disease to its key components, a computer-readable network of disease markers was characterised using genetic, biomarker, and clinical data; the model was also populated with ‘disease vs control’ data. Disease modelling Gulf War Illness. Tinker, tailor, soldier, therapy.

In-Vivo

In-Vivo Research Genetics Drugs

Sana Bio’s $150 Million IPO Expected to Provide Market Valuation of $10 Billion

The Pharma Data

JANUARY 17, 2021

Based in Seattle, Washington, Sana focuses on in vivo and ex vivo cell engineering platforms to develop therapies for cancer, diabetes, cardiovascular disease, CNS disorders, and genetic diseases. Launched in 2019, the company raised $700 million in June 2020 in its initial financing.

In-Vivo

In-Vivo Marketing Engineer Genetics

10 Key Learnings from Successful Cellular and Gene Therapy Trials for Rare Diseases

XTalks

APRIL 24, 2023

Approximately 72 percent of rare diseases are genetic, and around 70 percent of rare genetic diseases emerge in childhood. Rare diseases can often be progressive, chronic and fatal. Sadly, one-third of children with rare diseases die before their first birthday.

Gene Therapy

Gene Therapy Gene Trials Clinical Trials

Lyfgenia and Casgevy Become First FDA-Approved Gene Therapies for Sickle Cell Disease

XTalks

DECEMBER 13, 2023

The recurrence of these events, or crises, can lead to life-threatening disabilities and/or early death. The landmark approvals were awarded to bluebird bio’s Lyfgenia (lovo-cel) and Vertex Pharmaceuticals and CRISPR Therapeutics’ jointly developed Casgevy (exa-cel). Casgevy is also the first ever CRISPR/Cas9-based therapy approved in the US.

Gene Therapy

Gene Therapy Gene FDA Approval In-Vivo

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

XTalks

AUGUST 17, 2020

This typically involves taking T cells from the body, engineering chimeric receptor antigens (CAR) and inserting them into the cells, expanding the cells ex vivo and injecting them back into the body. Cell-Based Immunotherapy vs. Immune Biologics. Immunotherapy involves leveraging components of the immune system (i.e.

Protein

Protein Engineer Immune Response In-Vivo

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

The Pharma Data

DECEMBER 9, 2020

The creation of Overland isn’t the only exciting thing happening for international life sciences companies and organizations. A solution could be at hand with Overland Pharmaceuticals. Overland aims to build a leading, fully integrated biopharma company by leveraging global networks and formative R&D partnerships.

In-Vivo

In-Vivo In-Vitro Antibody Development

Combining the Powers of Single Cell Sequencing and AI in Understanding Disease Biology and Drug Development

XTalks

AUGUST 5, 2020

In recent webinars by Genuity Science, formerly known as WuXi NextCODE, experts from the biotech and pharma industries spoke about leveraging the power of single cell RNA sequencing platforms and solutions in conjunction with machine learning technologies such as AI in cell biology and disease research. The Power of Single Cell Technology.

Gene Expression

Gene Expression Development RNA Drugs

Verily – Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis

Delveinsight

FEBRUARY 11, 2021

Verily, Google’s life-science-focused sibling company and Janssen will also seek to tap into the data generated by people during their everyday lives to seek for any previous health-related signals in the two years leading up to the point they consented to participate in the study as well as in the two years after.

Gene Therapy

Gene Therapy Gene Immune Response In-Vivo

BioSpace Movers & Shakers, Oct. 16

The Pharma Data

OCTOBER 15, 2020

Assembly Biosciences – Former Gilead Sciences CEO John McHutchison, currently president and CEO of Assembly, was named the recipient of the Advance 2020 Global Impact award. The award honors McHutchison’s work in developing life-changing and curative therapies for patients with the hepatitis C virus. BeyondSpring – BeyondSpring Inc.

In-Vivo

In-Vivo Business Development Manufacturing Development

Exa-Cel CRISPR Gene Therapy for Sickle Cell Disease Deemed Safe by FDA Advisory Panel

XTalks

NOVEMBER 3, 2023

CRISPR works as genetic scissors to edit parts of the genome. Related: Intellia Gets FDA Clearance to Start First Ever Phase III Trial for an In Vivo CRISPR Drug The advisors appeared convinced that exa-cel can offer significant benefits to people with sickle cell. I think in this case, there is a huge unmet need.”

Gene Therapy

Gene Therapy Gene Gene Editing In-Vivo

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

OCTOBER 1, 2020

A life-changing moment came for Dr. Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. The journey first starts with the decision to make the switch. Key Moments.

Scientist

Scientist In-Vitro Research Life Science

CapstanTx secures $165 million to deliver precise in vivo cell engineering

pharmaphorum

SEPTEMBER 15, 2022

Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo engineering technology. Our ambition at Capstan is to invent new clinical paradigms through targeted in vivo reprogramming of cells.

In-Vivo

In-Vivo Engineer Scientist Life Science

Poseida Joins Roche in $1.5B Deal to Deliver Next-Gen CAR-T Therapies

XTalks

NOVEMBER 29, 2024

Kristin Yarema, President of Cell Therapy at Poseida Therapeutics – Xtalks Life Science Podcast Ep. Poseida’s genetic engineering platforms stand out for their precision, safety and potential to open new therapeutic avenues. Poseida’s expertise in donor-derived, allogeneic CAR-T therapies offers a transformative edge.

Gene Therapy

Gene Therapy Gene Gene Editing Genetic Engineering

Merus’ Bizengri Gets FDA Accelerated Approval for NSCLC and Pancreatic Adenocarcinoma with NRG1 Gene Fusions

XTalks

DECEMBER 6, 2024

Zenocutuzumab-zbco is a first-in-class bispecific antibody that targets NRG1 fusions, a rare genetic driver implicated in several tumor types. Zenocutuzumab-zbco is a first-in-class bispecific antibody that targets NRG1 fusions, a rare genetic driver implicated in several tumor types. percent of NSCLC and 0.3 months to 16.6

Gene

Gene In-Vivo In-Vitro Genetics

Clinical Research Informer

Life Science Trends to Look Out for in 2024

Intellia Gets FDA Clearance to Start First Ever Phase III Trial for an In Vivo CRISPR Drug

Webinars

Trending Sources

Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective

Webinars

Gulf War Illness: How can disease modelling aid the search for a cure?

Sana Bio’s $150 Million IPO Expected to Provide Market Valuation of $10 Billion

10 Key Learnings from Successful Cellular and Gene Therapy Trials for Rare Diseases

Lyfgenia and Casgevy Become First FDA-Approved Gene Therapies for Sickle Cell Disease

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

Combining the Powers of Single Cell Sequencing and AI in Understanding Disease Biology and Drug Development

Verily – Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis

BioSpace Movers & Shakers, Oct. 16

Exa-Cel CRISPR Gene Therapy for Sickle Cell Disease Deemed Safe by FDA Advisory Panel

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

CapstanTx secures $165 million to deliver precise in vivo cell engineering

Poseida Joins Roche in $1.5B Deal to Deliver Next-Gen CAR-T Therapies

Merus’ Bizengri Gets FDA Accelerated Approval for NSCLC and Pancreatic Adenocarcinoma with NRG1 Gene Fusions

Stay Connected